TCGA-34-5929-01A-11R-1820-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.490
- INTERFERON_ALPHA_RESPONSE+0.450
- G2M_CHECKPOINT+0.420
- E2F_TARGETS+0.410
- MYC_TARGETS_V1+0.410
- WNT_BETA_CATENIN_SIGNALING+0.330
- MITOTIC_SPINDLE+0.270
- DNA_REPAIR+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.240
- MTORC1_SIGNALING+0.190
Top 10 suppressed
- COAGULATION-0.340
- KRAS_SIGNALING_UP-0.280
- ALLOGRAFT_REJECTION-0.270
- XENOBIOTIC_METABOLISM-0.270
- IL6_JAK_STAT3_SIGNALING-0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- COMPLEMENT-0.210
- FATTY_ACID_METABOLISM-0.210
- INFLAMMATORY_RESPONSE-0.200
- ADIPOGENESIS-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-34-5231-01A-21R-1820-07 | — | cohortSQ2 | 0.868 |
| 2 | TCGA-E2-A109-01A-11R-A10J-07 | — | B | 0.829 |
| 3 | TCGA-63-7023-01A-11R-1949-07 | — | cohortSQ2 | 0.817 |
| 4 | TCGA-NC-A5HG-01A-11R-A26W-07 | — | cohortSQ1 | 0.816 |
| 5 | MNG163 | — | — | 0.809 |
| 6 | TCGA-77-A5GF-01A-21R-A27Q-07 | — | cohortSQ2 | 0.806 |
| 7 | MBCProject_1160_T2_RNA | — | E | 0.804 |
| 8 | BS_B1C6GZ84 | Diffuse intrinsic pontine glioma | — | 0.795 |
| 9 | 1c7309b2-91f0-4305-aad7-f86c0d143559 | — | — | 0.786 |
| 10 | MNG387 | — | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |